相似文献
1
Medicinal chemical properties of successful central nervous system drugs.
NeuroRx. 2005 Oct;2(4):541-53. doi: 10.1602/neurorx.2.4.541.
2
CNS drug design: balancing physicochemical properties for optimal brain exposure.
J Med Chem. 2015 Mar 26;58(6):2584-608. doi: 10.1021/jm501535r. Epub 2015 Jan 6.
3
On the future development of optimally-sized lipid-insoluble systemic therapies for CNS solid tumors and other neuropathologies.
Recent Pat CNS Drug Discov. 2010 Nov;5(3):239-52. doi: 10.2174/157488910793362403.
4
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. doi: 10.1124/jpet.102.039255.
5
CNS Physicochemical Property Space Shaped by a Diverse Set of Molecules with Experimentally Determined Exposure in the Mouse Brain.
J Med Chem. 2017 Jul 27;60(14):5943-5954. doi: 10.1021/acs.jmedchem.6b01469. Epub 2017 Apr 7.
6
Start small and stay small. Minimizing attrition in the clinic with a focus on CNS therapeutics.
Curr Top Med Chem. 2009;9(18):1688-704. doi: 10.2174/156802609790102374.
7
The blood-brain barrier: bottleneck in brain drug development.
NeuroRx. 2005 Jan;2(1):3-14. doi: 10.1602/neurorx.2.1.3.
8
Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery.
NeuroRx. 2005 Oct;2(4):554-71. doi: 10.1602/neurorx.2.4.554.
9
Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties.
ACS Chem Neurosci. 2010 Jun 16;1(6):435-49. doi: 10.1021/cn100008c. Epub 2010 Mar 25.
10
Assessment of the classification abilities of the CNS multi-parametric optimization approach by the method of logistic regression.
SAR QSAR Environ Res. 2016 Aug;27(8):629-35. doi: 10.1080/1062936X.2016.1212922. Epub 2016 Aug 1.
引用本文的文献
1
Design, Synthesis, and Molecular Docking Studies of Novel Pyrazoline-Thiazoles as Cholinesterase Dual-Target Inhibitors for the Treatment of Alzheimer's Disease.
ACS Omega. 2025 Aug 22;10(34):38427-38439. doi: 10.1021/acsomega.5c01055. eCollection 2025 Sep 2.
2
Overcoming the Blood-Brain Barrier: Advanced Strategies in Targeted Drug Delivery for Neurodegenerative Diseases.
Pharmaceutics. 2025 Aug 11;17(8):1041. doi: 10.3390/pharmaceutics17081041.
3
In Silico and In Vivo Pharmacological Evaluation of Iridoid Compounds: Geniposide and Asperuloside Profile Study Through Molecular Docking Assay and in the Model.
Biomolecules. 2025 Jul 31;15(8):1105. doi: 10.3390/biom15081105.
4
Opportunities for and Challenges of Pulmonary Drug Delivery in the Management of Acute Exacerbations of CNS Disorders.
CNS Drugs. 2025 Aug 7. doi: 10.1007/s40263-025-01213-4.
5
Antagonistic Trends Between Binding Affinity and Drug-Likeness in SARS-CoV-2 Mpro Inhibitors Revealed by Machine Learning.
Viruses. 2025 Jun 30;17(7):935. doi: 10.3390/v17070935.
6
Differential Modulation of Copper(II) Interactions with the 18-22 Coordinating Amylin Fragment by the Geometric Isomers of a New Nicotinoyl Hydrazone: A First Study.
ACS Omega. 2025 Jul 11;10(28):31115-31127. doi: 10.1021/acsomega.5c04850. eCollection 2025 Jul 22.
7
Discovery of -(6-Methoxypyridin-3-yl)quinoline-2-amine Derivatives for Imaging Aggregated α-Synuclein in Parkinson's Disease with Positron Emission Tomography.
Cells. 2025 Jul 18;14(14):1108. doi: 10.3390/cells14141108.
8
Network pharmacology and molecular dynamics simulation reveal antineoplastic potential of Antarctic sponge-derived suberitenones.
Front Chem. 2025 May 27;13:1545834. doi: 10.3389/fchem.2025.1545834. eCollection 2025.
9
Decarboxylative sulfation by persulfates.
Chem Sci. 2025 May 29. doi: 10.1039/d5sc03129j.
10
5'-Guanidino Xylofuranosyl Nucleosides as Novel Types of 5'-Functionalized Nucleosides with Biological Potential.
Pharmaceuticals (Basel). 2025 May 16;18(5):734. doi: 10.3390/ph18050734.
本文引用的文献
1
Lead- and drug-like compounds: the rule-of-five revolution.
Drug Discov Today Technol. 2004 Dec;1(4):337-41. doi: 10.1016/j.ddtec.2004.11.007.
2
Cytochrome p450 in silico: an integrative modeling approach.
J Med Chem. 2005 Apr 21;48(8):2725-55. doi: 10.1021/jm040180d.
3
The blood-brain barrier and neurotherapeutics.
NeuroRx. 2005 Jan;2(1):1-2. doi: 10.1602/neurorx.2.1.1.
4
Time-related differences in the physical property profiles of oral drugs.
J Med Chem. 2004 Dec 2;47(25):6338-48. doi: 10.1021/jm049717d.
5
Constructing optimum blood brain barrier QSAR models using a combination of 4D-molecular similarity measures and cluster analysis.
J Chem Inf Comput Sci. 2004 Nov-Dec;44(6):2083-98. doi: 10.1021/ci0498057.
6
QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.
Med Res Rev. 2005 Mar;25(2):133-66. doi: 10.1002/med.20019.
7
In silico prediction models for blood-brain barrier permeation.
Curr Med Chem. 2004 Jun;11(12):1617-28. doi: 10.2174/0929867043365071.
8
The many roles of computation in drug discovery.
Science. 2004 Mar 19;303(5665):1813-8. doi: 10.1126/science.1096361.
9
Predicting undesirable drug interactions with promiscuous proteins in silico.
Drug Discov Today. 2004 Mar 15;9(6):276-85. doi: 10.1016/S1359-6446(03)03008-3.
10
Drug transport at the blood-brain barrier and the choroid plexus.
Curr Drug Metab. 2004 Feb;5(1):95-108. doi: 10.2174/1389200043489126.
Zotero 插件